Tyra Biosciences Inc (TYRA) Stock AnalysisTYRATyra Biosciences Inc

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Tyra Biosciences Inc is currently priced at $19.94, which is significantly below the average analyst price target of $39.75, indicating potential upside. However, the stock has a low RSI of 26.423, suggesting it is oversold, but the negative earnings trend with a forward P/E of 0 and a consistent decline in net income raises concerns. The main risk is the insider selling activity, which has increased by 100.98% over the last month, indicating potential lack of confidence from insiders.